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Azithromycin is an effective treatment for uncomplicated infections with Salmonella enterica serovar Typhi and serovar Paraty-
phi A (enteric fever), but there are no clinically validatedMIC and disk zone size interpretative guidelines. We studied individual
patient data from three randomized controlled trials (RCTs) of antimicrobial treatment in enteric fever in Vietnam, with azi-
thromycin used in one treatment arm, to determine the relationship between azithromycin treatment response and the azithro-
mycinMIC of the infecting isolate. We additionally compared the azithromycinMIC and the disk susceptibility zone sizes of
1,640 S. Typhi and S. Paratyphi A clinical isolates collected from seven Asian countries. In the RCTs, 214 patients who were
treated with azithromycin at a dose of 10 to 20 mg/ml for 5 to 7 days were analyzed. Treatment was successful in 195 of 214 (91%)
patients, with no significant difference in response (cure rate, fever clearance time) withMICs ranging from 4 to 16g/ml. The
proportion of Asian enteric fever isolates with anMIC of<16g/ml was 1,452/1,460 (99.5%; 95% confidence interval [CI], 98.9
to 99.7) for S. Typhi and 207/240 (86.3%; 95% CI, 81.2 to 90.3) (P< 0.001) for S. Paratyphi A. A zone size of>13 mm to a 5-g
azithromycin disk identified S. Typhi isolates with anMIC of<16g/ml with a sensitivity of 99.7%. An azithromycinMIC of
<16g/ml or disk inhibition zone size of>13 mm enabled the detection of susceptible S. Typhi isolates that respond to azithro-
mycin treatment. Further work is needed to define the response to treatment in S. Typhi isolates with an azithromycinMIC of
>16g/ml and to determineMIC and disk breakpoints for S. Paratyphi A.
Enteric fever, caused by Salmonella enterica serovars Typhi andParatyphi A, is common among febrile patients in regions of
the world that have poor standards of hygiene and sanitation. It
has been estimated that there may be as many as 27 million new
infections of enteric fever each year (1). Although the disease can
be treated and complications can be prevented by the use of ap-
propriate antimicrobials, antimicrobial-resistant strains of S. Ty-
phi and S. Paratyphi A have become common in regions of ende-
micity, which has made treatment selection a challenge (2).
Multidrug-resistant (MDR) strains (exhibiting resistance to
chloramphenicol, trimethoprim-sulfamethoxazole, and ampicil-
lin) and those with intermediate susceptibility or resistance to
fluoroquinolones such as ciprofloxacin and ofloxacin are now
widespread in Asia and Africa (3–6). Extended-spectrum cepha-
losporins such as ceftriaxone and cefixime are commonly used for
infections caused by MDR organisms and in children, although
these tend to be associated with slower fever clearance times
(FCTs), and sporadic reports of extended-spectrum beta-lacta-
mase (ESBL)-producing isolates are a concern (7).
Several randomized clinical trials (RCTs) have established the
azalide antimicrobial azithromycin to be an effective alternative
oral treatment for uncomplicated enteric fever. Treatment dura-
tions of 5 to 7 days lead to the resolution of symptoms with gen-
erally low rates of relapse and convalescent-stage fecal carriage
(8–14). Given the trends of antimicrobial resistance in enteric
fever, azithromycin is likely to become one of the few universally
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efficacious antimicrobials for treating the disease. Therefore, the
laboratory detection and identification of strains with decreased
susceptibility or resistance to azithromycin is important for clini-
cians treating individual patients and for public health organiza-
tions setting routine treatment guidelines. Current guidelines
have no clinically validated interpretive ranges for azithromycin
MICs or disk susceptibility breakpoints for Salmonella isolates.
The epidemiological surveillance of bacterial populations has led
to the recommendation that an azithromycin MIC of16 g/ml
be considered susceptible for invasive isolates of Salmonella
(15–17).
To address these knowledge gaps in the use of azithromycin for
treating enteric fever, we aimed to examine the relationship be-
tween the MIC against azithromycin of infecting isolates and the
clinical response to azithromycin in adults and children recruited
to three RCTs of enteric fever conducted in Vietnam. We addi-
tionally aimed to study the relationship between azithromycin
MIC distribution and disk inhibition zone size in over 1,500 clin-
ical isolates of S. Typhi and S. Paratyphi A from seven Asian coun-
tries. Using these data, we propose evidence-derivedMIC anddisk
susceptibility test breakpoints for azithromycin treatment in en-
teric fever.
MATERIALS AND METHODS
Ethics statement. The study was conducted according to the principles
expressed in the Declaration of Helsinki. The RCTs on which the data for
this study were derived were approved by the Institutional Review Board
of theHospital for Tropical Diseases and the additional hospitals involved
in the studies. All patients in the clinical trials provided informed consent
(informedconsentwasprovidedby theparentsor guardianof childrenunder
18 years of age) for the collection of samples and subsequent analysis.
SalmonellaTyphi and SalmonellaParatyphiA strain collection.The
Salmonella Typhi and Salmonella Paratyphi A strains used in this study
were isolates collected from blood culture, and occasionally from bone
marrow or fecal culture, as part of the routine diagnostic activities of
microbiology laboratories in seven countries. The participating laborato-
ries were the following: The Hospital for Tropical Diseases, Ho Chi Minh
City, Vietnam; Dong Thap Provincial Hospital, Dong Thap Province,
Vietnam; An Giang Provincial Hospital, An Giang Province, Vietnam;
Angkor Hospital for Children, Siem Reap, Cambodia; Mahosot Hospital,
Vientiane, Laos; Shoklo Malaria Research Unit, Mae Sot, Thailand; Chit-
tagong Medical College Hospital, Chittagong, Bangladesh; Patan Hospi-
tal, Kathmandu, Nepal; and Safdarjung Hospital, New Delhi, India. Only
one isolate (the strain isolated on admission to the health care facility)
from each patient was included for microbiological examination and
analysis.
Microbiological methods. The isolates were identified by standard
biochemical tests and agglutinationwith Salmonella-specific antisera. An-
timicrobial susceptibility tests were performed at the time of isolation by
the modified Kirby-Bauer disk diffusion method, with zone sizes mea-
sured and recorded. Zone size interpretation was based on the 2013 CLSI
guidelines (15). The antimicrobial disks tested were chloramphenicol
(CHL; 30g), trimethoprim-sulfamethoxazole (SXT; 1.25 and 23.75g),
ampicillin (AMP; 10 g), ceftriaxone (CRO; 30 g), ofloxacin (OFX; 5
g), ciprofloxacin (CIP; 5 g), nalidixic acid (NAL; 30 g), and azithro-
mycin (AZM; 5 g). An isolate was defined as MDR if it was resistant to
chloramphenicol, trimethoprim-sulfamethoxazole, and ampicillin by
disk susceptibility testing. An isolate was defined as having intermediate
susceptibility to ciprofloxacin if it was resistant to nalidixic acid or had a
ciprofloxacin MIC of 0.125 to 0.5 g/ml and resistant if the ciprofloxacin
MIC was1.0 g/ml.
At the time of isolation, or after a period of storage at 20°C or
80°C, the MICs of the isolates were determined by the standard agar
plate dilution method according to CLSI guidelines with a targeted final
inoculum of 5 105 CFU/ml (18) or by Etest, according to manufactur-
er’s recommendations (AB Biodisk, Sweden). Azithromycin powder for
the agar plate dilution MICs was a gift from Pfizer, United Kingdom.
Escherichia coliATCC 25922 and Staphylococcus aureusATCC 29213 were
used as control strains for these assays.
Analysis of isolates for macrolide resistance genes. The presence of
macrolide resistance genes was determined in available isolates that had
an elevatedMIC to azithromycin (16g/ml) and/or a decreased zone of
inhibition, 18 mm, to an azithromycin 5-g disk. Genomic DNA was
extracted using theWizardGenomicDNAkit (Promega,Madison,WI) as
per themanufacturer’s instruction and investigated by PCR amplification
to detect mphA, ermA, ermB, ermV, ereA, ereB, mefA, and msrA genes
using published methods (19). All PCRs included positive and negative
controls.
Randomized controlled trials.We analyzed the results of three open
RCTs conducted in southern Vietnam between 1997 and 2005, in which
azithromycin was used for the treatment of enteric fever in one of the trial
arms (10, 13, 14). All the RCTs were conducted using a standard protocol,
except for the dose and duration of azithromycin treatment and the alter-
native treatment regimens used. The RCTs were conducted at three study
sites in southern Vietnam: The Hospital for Tropical Diseases, Ho Chi
Minh City (10, 14); Dong Thap Provincial Hospital, Cao Lanh, Dong
Thap Province (13, 14); and An Giang Provincial Hospital, Long Xuyen,
An Giang Province (14).
Clinical procedures. Patients with suspected uncomplicated enteric
fever were allocated to one of each of the treatment groups in an open
randomized comparison. A computer-generated randomization list was
produced by an administrator whowas not otherwise involved in the trial.
The treatment allocations were kept in serially numbered sealed opaque
envelopes that were opened only after the patient had been enrolled into
the study. The treatment arms were azithromycin (Zithromax suspen-
sion, 200 mg/5 ml; or Zithromax tablets, 500 mg/tablet; both from Pfizer,
USA) at a dose that varied between 10 and 20 mg/kg of body weight/day
orally in a single daily dose (maximum, 1 g daily) for 5 days (10) or 7 days
(13, 14). The comparator arms were ofloxacin (10, 13), a combination of
ofloxacin and azithromycin (13), or gatifloxacin (14). Hematocrit, white
cell, platelet, and blood differential counts were performed with serum
aspartate transaminase, alanine transaminase, creatinine levels, and uri-
nalysis before therapy was initiated. Aspartate transaminase and alanine
transaminase measurements were repeated 1 day after the end of therapy.
A full blood count was repeated if there was a suggestion of gastrointesti-
nal bleeding or clinical evidence of anemia.
Patients were excluded if they refused consent, had evidence of wors-
ening or complicated disease, had inability to swallow oral medication,
had a history of significant underlying disease, had hypersensitivity to
either of the trial drugs, or were pregnant or lactating. Additionally, pa-
tients who gave a history of treatment with a fluoroquinolone, a third-
generation cephalosporin, or a macrolide within 1 week of hospital ad-
mission were also excluded.
Clinical definitions. In all three studies, patients were examined daily,
with axillary temperature measured every 6 h, until discharge from hos-
pital, with particular reference to clinical symptoms and complications of
the disease. Response to treatment was assessed by the resolution of clin-
ical symptoms and signs, the fever clearance time (time from the start of
treatment until the axillary body temperature reached 37.5°C and re-
mained at this temperature for at least 48 h), the development of compli-
cations or death, any evidence of relapse of infection, and persistent fecal
carriage after the conclusion of treatment or at the 1-month follow-up
visit.
Clinical treatment failure was defined as the persistence of fever
(37.5°C) and other enteric fever-related symptoms formore than 2 days
after the end of treatment or the development of severe complications
(severe gastrointestinal bleeding, intestinal perforation, visible jaundice,
myocarditis, pneumonia, renal failure, shock, or an altered consciousness
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level, i.e., with a Glasgow coma score [GCS] of15/15) during treatment
and the need for rescue treatment in the judgment of the treating clinician.
Microbiological treatment failure was defined as isolation of Salmonella
Typhi or Salmonella Paratyphi A from blood or a sterile site after the
completion of treatment. Poststudy fecal carriage was defined as a positive
fecal culture, with an isolate having the same susceptibility pattern as the
original isolate, after the end of the initial treatment and before hospital
discharge.
Patientswere requested to return for a follow-up assessment at 4weeks
or earlier if their symptoms recurred, and then at 3 and 6months. Clinical
evidence of relapse was sought, and one fecal culture was performed. A
blood culture was performed if the symptoms and signs suggested relapse.
A relapse was defined as a recurrence of symptoms and signs suggestive of
enteric fever within the 4-week period after the patient had been dis-
charged as healthy from the hospital accompanied by a blood culture
positive for Salmonella Typhi or Salmonella Paratyphi A. Fecal carriage
was defined as a positive fecal culture at a follow-up visit, with an isolate
having the same susceptibility pattern as the original isolate.
Statistical analysis. Analysis of the RCTs was restricted to patients in
whom S. Typhi or S. Paratyphi Awas isolated fromblood or bonemarrow
culture prior to treatment with azithromycin and for whom the azithro-
mycin MIC of the original infecting isolate had been determined. The
pooled admission and outcome data for individual patients were com-
piled with respect to the azithromycin MIC of the original infecting iso-
TABLE 1 Demographic, clinical, and microbiological features of patients with uncomplicated enteric fever treated with azithromycin from three
randomized trials
Variable
Valuea for patients with infecting isolate azithromycin MIC of:
P value4 g/ml 6–8 g/ml 12–16 g/ml
No. of patients 13 116 85
Age (yr) 14 (9–17) 14 (9–21) 11 (8–19) 0.256
Male sex (%) 8 (61.5) 59 (50.9) 35 (41.2) 0.233
Days of illness (IQR) 9 (6–14) 8 (6–10) 7 (5–10) 0.078
Patients from Dong Thap/An Giang (%) 8 (61) 78 (73) 79 (93) 0.001
Patients from HCMCb (%) 5 (39) 31 (27) 6 (7)
Headache (%) 9 (69) 31 (75) 58 (68) 0.582
Cough (%) 3 (23) 28 (24) 27 (32) 0.428
Vomiting (%) 5 (39) 41 (35) 31 (37) 0.969
Abdominal pain (%) 4 (31) 55 (47) 43 (51) 0.410
Constipation (%) 1 (8) 12 (10) 24 (29) 0.002
Diarrhea (%) 8 (62) 86 (74) 54 (64) 0.227
Antimicrobial pretreatment (%) 1 (8) 20 (17) 10 (12) 0.252
Admission temp (°C) 39.5 (39.0–39.9) 39.0 (38.9–40.0) 39.0 (38.5–39.5) 0.677
Hepatomegaly (%) 7 (54) 47 (41) 41 (48) 0.431
Splenomegaly (%) 1 (8) 9 (8) 7 (8) 0.994
Hematocrit (%) 38 (34–40) 37 (32–40) 34 (31–38) 0.041
White cell count (109/liter) 7.7 (5.5–9.2) 6.8 (5.0–8.3) 7.2 (5.5–8.8) 0.326
Neutrophil (%) 72 (63–79) 66 (55–73) 67 (58–76) 0.316
Lymphocytes (%) 19 (15–35) 29 (20–37) 26 (19–35) 0.378
Platelets (109/liter) 213 (187–270) 166 (120–213) 175 (140–259) 0.004
AST (IU/liter) 154 (68–202) 77 (44–131) 96 (60–145) 0.065
ALT (IU/liter) 100 (38–221) 63 (40–103) 69 (43–127) 0.207
S. Typhi (%) 13 (6) 115 (55) 81 (39) 0.173
S. Paratyphi A (%) 0 (0) 1 (20) 4 (80)
MDR isolatec (%) 7 (54) 78 (67) 52 (61) 0.495
Ciprofloxacin intermediate (%) 8 (62) 102 (88) 74 (87) 0.032
a Values are medians (IQR) of given unit or numbers (%).
b HCMC, The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.
c MDR, multidrug resistant (resistant to chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole).
TABLE 2 Clinical response to azithromycin in relation to the azithromycin MIC of the infecting isolate in enteric fever treatmenta
Variable
Value for patients with infecting isolate azithromycin MIC of:
P value4 g/ml 6–8 g/ml 12–16 g/ml
No. of patients 13 116 85
Median duration (IQR) to fever clearance time (days) 4.4 (3.7–4.5) 4.9 (3.4–7.5) 4.7 (3.2–7.0) 0.249
Any failure (%) 1 (8) 9 (8) 9 (11) 0.775
Clinical failure (%) 1 (8) 9 (8) 8 (9) 0.912
Microbiological failure (%) 1 (8) 1 (1) 3 (4) 0.195
Complicated disease (%) 0 (0) 4 (3) 6 (7) 0.347
Median duration (range) of hospital stay (days) 12 (11–14) 13 (12–15) 13 (12–15) 0.714
Convalescent-stage fecal carriage (%) 0/10 (0) 0/98 (0) 3/72 (4)
Relapse (%) 0/10 (0) 0/98 (0) 0/72 (0)
a Unless otherwise indicated, values are numbers (%) of patients exhibiting the response.
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late. Proportions were compared with the chi-square test, Fisher’s exact
test, or analysis of variance. Normally distributed data were compared
using the Student t test, and nonnormally distributed data were compared
using the Mann-Whitney U test or the Kruskal-Wallis test. The fever
clearance times were compared using survival analysis and the log rank
test. Independent risk factors for clinical failure in the clinical trials were
determined by multivariate logistic regression; a P value of 0.05 was
considered significant. Statistical analysis was performed using SPSS for
Windows version 21 (SPSS Inc., Chicago, IL, USA).
For the microbiology data, an MIC histogram was constructed, and
the MIC50 and MIC90 values were calculated. The disk zone diameter
breakpoints were selected by the modified error rate-bounded method of
Metzler and DeHaan and adjusted until the number of very major (false-
susceptible) and major (false-resistant) errors had been minimized (20).
The proposed MIC breakpoints for susceptibility based on the clinical
data were 16 g/ml. Guidelines for acceptable discrepancy rates were
according to the CLSI recommendation (21). Because of the inherent1
dilution variation in MIC testing for each serovar, discrepancy rates were
calculated for the susceptible MIC 1 dilution, the susceptible and resis-
tantMICs, and the resistantMIC 1 dilution. For the zone size interpre-
tive criteria, the following acceptable discrepancy rates have been estab-
lished by the CLSI: for R  S, 10% very major and 10% major
discrepancies; for R 1, 2% very major discrepancies; and for S 1, 2%
major discrepancies (21).
RESULTS
Analysis of randomized controlled trials. There were 248 cul-
ture-positive patients randomized to azithromycin in the three
trials. In 34 of these patients, the bacterial isolate was not available
for rechecking the azithromycin susceptibility pattern, leaving 214
patients eligible for analysis. This final data set of 214 patients had
amedian age of 13 years (interquartile range [IQR], 8 to 20; range,
1 to 68) and a median duration of illness prior to admission of 8
days (IQR, 6 to 10; range, 2 to 30). The infecting isolate was S.
Typhi in 209 patients and S. Paratyphi A in 5 patients. A total of
137 (64%) isolates were MDR, 184 (86%) were intermediate to
ciprofloxacin, and none were ciprofloxacin resistant. All isolates
were susceptible to ceftriaxone. The median azithromycin MIC
was 8 g/ml (IQR, 8 to 12; range, 4 to 16). The demographic,
clinical, and microbiological features of the patients grouped by
the azithromycin MIC are shown in Table 1. There were no sig-
nificant differences between the three groups, but isolates with an
MIC of 12 to 16 g/ml were more likely to be isolated from pa-
tients in the studies conducted in the Mekong Delta (13, 14).
The response to treatment in relation to the azithromycinMIC
of the infecting isolate is shown in Table 2; 195 patients (91.1%;
95% CI, 86.3 to 94.4) successfully completed their treatment, and
19 patients failed treatment. Five treatment failures were micro-
biological failures with a positive blood culture after the comple-
tion of treatment, and 18 were clinical failures due to persisting
fever and symptoms on the 10th day, including 10 patients who
developed a complication. Some failed in more than one of these
categories. Themedian (IQR, range) FCTwas 4.8 (3.3 to 7.2, 0.5 to
13.5) days, and the median (IQR, range) duration of hospital stay
was 13 (12 to 15, 9 to 26) days. A Kaplan-Meier curve analysis of
the FCT found no significant difference in the clinical response to
azithromycin according to theMICof the infecting isolate (Fig. 1).
Longitudinal posttreatment follow-up was possible in 180 pa-
tients as follows: on a single follow-up occasion in 23 patients, on
two occasions in 66 patients, and on three occasions in 91 patients.
There were no recorded relapses. Three patients had a positive
fecal culture at the follow-up visit: two patients at the 1-month
follow-up visit and one patient at the 3-month follow-up visit.
None of these patients failed their initial course of treatment. Ta-
ble 3 outlines the association between demographics, clinical ob-
servations, treatment regimen, and microbiological factors
against treatment failure. We found no significant associations
between the selected variables and clinical failure by either a uni-
variate or a multivariate (data not shown) analysis.
Antimicrobial susceptibility testing of S. Typhi and S. Para-
typhi A isolates against azithromycin. We analyzed the antimi-
crobial susceptibility profiles and measured the zone sizes and
MICs against azithromycin in 1,700 invasive Salmonella isolates.
These strains were isolated in seven countries across Asia and
spanned 17 years; 1,460 of these were S. Typhi, and 240 were S.
Paratyphi A (Table 4). For the S. Typhi isolates, 510/1,460 (34.9%)
were MDR, 948/1,460 (64.9%) demonstrated intermediate sus-
ceptibility to ciprofloxacin, and 42/1,460 (2.9%) were ciprofloxa-
cin resistant. For S. Paratyphi A isolates, 0/240 (0%) were MDR,
184/240 (76.7%) demonstrated intermediate susceptibility to cip-
rofloxacin, and 27/240 (11.3%) were ciprofloxacin resistant. The
proportion of ciprofloxacin-nonsusceptible S. Paratyphi A iso-
lates was 211/240 (87.9%), significantly higher than the propor-
tion of S. Typhi isolates at 990/1,460 (67.8%) (P 0.001, Fisher’s
exact test).
The distribution of MICs against azithromycin of the 1,700
Salmonella isolates is shown in Fig. 2. The MICs against azithro-
mycin in the S. Typhi isolates were normally distributed and
ranged between 0.25 g/ml and 32 g/ml, with MIC50 and
MIC90 values of 6 g/ml and 12 g/ml, respectively. For the S.
Paratyphi A isolates, the MICs against azithromycin ranged from
1 g/ml to32 g/ml and the corresponding MIC50 and MIC90
values were 12 g/ml and 24 g/ml, respectively. The proportion
of S. Typhi isolates with anMIC of16g/ml against azithromy-
cin was 1,452/1,460 (99.5%; 95% CI, 98.9 to 99.7), and the corre-
sponding proportion for the S. Paratyphi A isolates was 207/240
(86.3%; 95%, CI 81.2 to 90.3) (P 0.001, Fisher’s exact test).
Azithromycin disk inhibition zone sizes were available for
1,062 of the S. Typhi isolates and 156 of the S. Paratyphi A isolates.
FIG 1 Clinical response to azithromycin in the treatment of enteric fever by
fever clearance time. Kaplan-Meier curves show the proportion of patients still
febrile after starting azithromycin according to the azithromycin MIC of the
infecting isolate.
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The relationships between azithromycin MIC and disk inhibition
zone size for S. Typhi and S. Paratyphi A are shown in Fig. 3. There
was a substantial spread of zone sizes in comparison to MICs; for
example, themajority of S. Typhi isolates (591/1,062 [55.6%]) had
an MIC of 8 g/ml, and the corresponding zone sizes spanned 12
to 27mm. Table 5 summarizes the proportion of false-susceptible
results (very major discrepancies) and false-resistant results (ma-
jor discrepancies) using an MIC breakpoint of 16 g/ml and a
zone size breakpoint of13 mm to a 5-g azithromycin disk for
susceptibility in S. Typhi isolates. The numbers of very major and
major errors all amounted to less than 2% and were within the
CLSI guidelines (22). When 32 g/ml was selected as the MIC
breakpoint and a zone of inhibition 13 mm to a 5-g azithro-
mycin disk for susceptible S. Paratyphi A isolates, the proportion
TABLE 3 Factors associated with treatment failure with azithromycin therapy for enteric fever
Variable
Valuea for treatment outcome
P value ORb (95% CI)Failure Success
No. of patients 19 195
Male sex (%) 12 (8–22) 13 (8–20) 0.966
Days of illness (IQR) 7 (4–14) 8 (6–10) 0.601
Male sex (%) 10 (52.6) 92 (47.2) 0.831 1.24 (0.44–3.51)
Mekong Delta site (%) 17 (89.5) 155 (79.5) 0.379 2.19 (0.49–20.3)
S. Typhi (%) 19 (100) 190 (97) 1.000
S. Paratyphi A (%) 0 (0) 5 (3)
MDR isolate (%) 15 (78.9) 122 (62.6) 0.242 2.24 (0.68–9.61)
Ciprofloxacin intermediate (%) 17 (89.5) 167 (85.6) 1.00 1.43 (0.31–13.4)
Azithromycin MIC8 g/ml (%) 9 (47.4) 76 (39.0) 0.640 1.41 (0.50–3.97)
Duration of azithromycin treatment7 days (%) 2 (10.5) 40 (20.5) 0.379 0.46 (0.05–2.06)
Dose of azithromycin 10 mg/kg (%) 5 (26.3) 40 (20.5) 0.559 1.38 (0.37–4.37)
a Values are medians (interquartile range) or numbers (%).
b OR, odds ratio.
TABLE 4 Organisms subjected to antimicrobial susceptibility and azithromycin MIC testing in this study
Country Serovar
No. of organisms collected in:
1995–2001 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total
Bangladesh Typhi 29 29
Paratyphi 3 3
Total 32 32
Cambodia Typhi 19 25 14 36 50 96 240
Paratyphi 0 3 0 0 0 0 3
Total 19 28 14 36 50 96 243
India Typhi 92 72 86 250
Paratyphi 20 15 20 55
Total 112 87 106 305
Laos Typhi 26 16 35 21 36 32 42 18 6 232
Paratyphi 0 0 0 0 0 1 0 0 0 1
Total 26 16 35 21 36 33 42 18 6 233
Nepal Typhi 47 67 21 29 4 1 379
Paratyphi 113 109 100 47 6 4 169
Total 160 176 121 76 10 5 548
Thailand Typhi 22 20 2 1 45
Paratyphi 0 0 0 0 0
Total 22 20 2 1 45
Vietnam Typhi 162 88 35 285
Paratyphi 5 1 3 9
Total 167 89 38 294
Total Typhi 162 114 164 144 254 200 140 83 68 131 1,460
Paratyphi 5 1 50 67 41 47 25 1 0 3 240
Total 167 115 214 211 295 247 165 84 68 134 1,700
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of major errors in the R  S group was 17.4% and that of major
errors in the S 1 group was 3.8%, both of which are outside the
acceptable CLSI guidelines limits.
We hypothesized that the strains with elevated MICs to azi-
thromycin (16 g/ml and/or zone of inhibition of 18 mm)
harbored plasmid-borne macrolide resistance genes. To investi-
gate their presence, we extracted genomic DNA from 39 S. Para-
typhi A isolates (Nepal [n 	 38], Cambodia [n 	 1]) and 40 S.
Typhi isolates (Nepal [n	 14], Cambodia [n	 15], Laos [n	 6],
Vietnam [n 	 5]). Despite the amplification of the appropriate
positive controls, we were unable to detect the presence ofmphA,
ermA, ermB, ermV, ereA, ereB, mefA, and msrA genes in these
isolates.
DISCUSSION
Interpretative breakpoints for disk susceptibility testing with an-
timicrobials used for treatment are necessary to assist clinicians in
the choice of therapy, for the collection of accurate surveillance
data, and for the detection of emerging resistance. The lack of
validated guidelines for azithromycin susceptibility in S. Typhi
and S. Paratyphi A is a significant problem in the clinical manage-
ment of enteric fever. The continued use of azithromycin in en-
teric fever infections with reduced susceptibility to azithromycin
may inadvertently drive the emergence and spread of azithromy-
cin-resistant isolates and lead to treatment failure. The establish-
ment of suitable breakpoints requires the evaluation of several
sources of evidence, including clinical outcome data, MIC distri-
butions for the pathogen, the investigation of potential resistance
mechanisms, and consideration of the pharmacodynamic and
pharmacokinetic properties of the antimicrobial (21).
Here we have analyzed three RCTs conducted in Vietnam. Pa-
tients with uncomplicated enteric fever treated with oral azithro-
mycin had a pooled success rate of 91% (95% CI, 86 to 94). The
trials were conducted according to similar protocols, although it
should be noted that the duration and dosage of azithromycin
treatment were not standard across all patient groups. The azi-
thromycin MIC of the isolates ranged between 4 g/ml and 16
g/ml, whichwe found to be typical of strains isolated across Asia.
We found no significant difference in the response to azithromy-
cin treatment according to the MIC of the infecting organism.
Furthermore, when combined with other clinical and treatment
factors, we found there to be no influence of azithromycinMICon
treatment outcome. These data predict that oral azithromycin is
an acceptable choice for treating adults and children with uncom-
plicated enteric fever, provided the azithromycin MIC of the in-
fecting strain is16 g/ml. We recognize that the optimum dose
and duration of treatment remain to be determined.
The lack of infections with isolates with anMIC of16 g/ml
is an obvious limitation of this study, and more information on
the response to treatment when patients are infected with strains
with higher MICs is needed. Furthermore, we had data from only
five patients fromwhoman S. Paratyphi A isolate was recovered in
the clinical trial analysis, and this lack of clinical data for S. Para-
typhi A is a further limitation. Antimicrobial-resistant S. Paraty-
phi A causes a significant burden of disease in Asia and may be
increasing.Worryingly, we found that S. Paratyphi A isolates were
significantly more likely to have an azithromycin MIC of 16
g/ml than S. Typhi isolates and were additionally more likely to
be ciprofloxacin nonsusceptible. Of note, in a case report of the
clinical failure of azithromycin treatment in enteric fever caused
by S. Paratyphi A, the isolate had an azithromycin MIC of 64
g/ml initially, and then theMICwas 256g/ml in a secondblood
culture (23). In this case, the specific mechanism of this resistance
was not described, and there are few reports on themechanisms of
resistance to azithromycin in Salmonella spp. Non-S. Typhi Sal-
monella strains with mutations in the rplD gene and containing
the mphA gene have been described previously (24). Here we did
FIG 2 Distribution of azithromycinMICs in S. Typhi and S. Paratyphi A. Histogram showing the azithromycinMIC distribution for 1,460 S. Typhi isolates and
240 S. Paratyphi A isolates from Bangladesh (n	 32), Cambodia (n	 243), India (n	 305), Laos (n	 233), Nepal (n	 548), Thailand (n	 45), and Vietnam
(n	 294).
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not identify any previously described macrolide resistance genes
in S. Paratyphi A strains with elevated MICs and/or reduced zone
sizes, but we did not exhaustively search for other mechanisms.
We suggest that further in vitro experiments be performed to un-
derstand how intrinsic increases in MIC may occur through
changes in transcription or posttranslational modification.
The isolates analyzed for MIC and disk susceptibility for the
purposes of this investigation were amalgamated from seven
countries across Asia, making this the biggest study of its type
providing evidence for azithromycin susceptibility breakpoints in
enteric fever. The majority of these strains were collected in the
last 10 years, although some Vietnamese isolates dated back to the
mid-1990s. For S. Typhi isolates, the majority had MICs ranging
between 4 and 12 g/ml with only 0.5% having an MIC of 16
g/ml. These data are consistent with previous data presented for
S. Typhi and non-S. Typhi Salmonella isolates and support the
concept of an ecological cutoff for wild-type S. Typhi of 16
g/ml of azithromycin, with isolates with an MIC of 16 g/ml
being considered non-wild-type strains (24, 25). A disk zone size
of 13 mm identified the majority of isolates with an MIC 16
g/ml. The breakpoint missed some isolates with a higher MIC,
although a limitation of this study is the lack of isolates with an
MIC of16 g/ml.
The MIC distribution against azithromycin in S. Paratyphi A
was not concordant with that of S. Typhi. The MICs in S. Paraty-
phi were skewed to the right, with 13.8%of isolates having anMIC
FIG 3 Relationship between azithromycinMIC and inhibition zone size in invasive Salmonella isolates. (A) Scatter plot ofMIC data from 1,062 S. Typhi isolates
fromBangladesh (n	 29), Cambodia (n	 240), India (n	 250), Nepal (n	 213), Thailand (n	 45), andVietnam (n	 285). (B) Scatter plot ofMIC data from
156 Salmonella serotype Paratyphi A isolates fromBangladesh (n	 2), Cambodia (n	 3), India (n	 52), Nepal (n	 90), and Vietnam (n	 9). Both plots show
the relationship between the MIC to azithromycin (y axis) and the inhibition zone diameters using a 5-g azithromycin disk.
TABLE 5 Proportion of false-susceptible and false-resistant results for
proposed azithromycin MIC breakpoints
Organism (susceptibility
breakpoint [g/ml]) MIC rangea
No. of
isolates
No. of discrepancies
(discrepancy rate
[%])
Very major Major
Typhi (16) R 1 1 0 NAb
R S 191 3 (1.6) 1 (0.5)
S 1 870 NA 4 (0.5)
Total 1,062 3 (0.3) 5 (0.5)
Paratyphi A (32) R 1 0 0 NA
R S 23 4 (17.4) 1 (4.3)
S 1 133 NA 5 (3.8)
Total 156 4 (2.6) 6 (3.8)
a S, susceptible MIC; R, nonsusceptible MIC.
b NA, not applicable.
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of16 g/ml. These data suggest that the epidemiological cutoff
forwild-type S. Paratyphi Amay be 32g/ml, which is higher than
that of the S. Typhi strains. A similar discordance between the
azithromycin susceptibilities of S. Typhi and S. Paratyphi A was
observed in a smaller study conducted in Kolkata, India (26). As
with the S. Typhi isolates, a disk zone size of 13 mm identified
the majority of S. Paratyphi A isolates with anMIC of32 g/ml
but missed some isolates with a higher MIC. The proportions of
very major and major errors using this disk breakpoint were not
within acceptable limits as recommended by the CLSI (21). Fur-
thermore, there were few isolates with anMIC of32g/ml. The
data from this study suggest that S. Paratyphi A and S. Typhi
cannot be assigned to the sameMIC breakpoint or zone diameter
criteria. S. Typhi and S. Paratyphi A are two serovars of the same
bacterial species, Salmonella enterica. The observed difference in
MIC distribution between the two serovars is not consistent with
the usual rule that the same species should have the same MIC
distribution regardless of the serovar. MIC data from other strain
collections are needed to confirm this difference.
We acknowledge that broth microdilution is the internation-
ally recognized reference method for MIC determination (ISO
20776-1 and -2) rather than the Etest or agar dilutionmethod, and
this is a limitation. We are not aware of a study formally compar-
ing the threemethods for azithromycinMIC testing in Salmonella
enterica. We further recognize that there may have been some
variation in the performances of the susceptibility tests performed
across the different sites, by different scientists, and using different
reagent manufacturers, although all sites adhere to CLSI guide-
lines. Test factors such as pH and inoculum have been shown to
have important effects on azithromycin susceptibility testing of
Salmonella (27). Furthermore, themargin of the zone of inhibited
growth around the azithromycin diskmay not be clear andmay be
difficult to interpret accurately.
Azithromycin is an azalide antimicrobial with excellent tissue
penetration (28). It achieves concentrations in macrophages and
neutrophils that are 100-fold higher than those measured in
serum (29, 30). The drug also has a half-life of 2 to 3 days, which
allows once-a-day dosing (28). The pharmacokinetic-pharmaco-
dynamic (PK-PD) parameters predictive for the efficacy for azi-
thromycin in enteric fever have not been determined, but in other
studies, free drug area under the concentration-time curve from 0
to 24 h/MIC ratio (AUC24H/MIC ratio) was the parameter found
to be most predictive of efficacy (31). It may be that levels of
azithromycin in plasma and an in vitroMIC result are not the best
measures of efficacy for this antimicrobial, which is highly con-
centrated at the site of intracellular infection. The pharmacokinet-
ics of azithromycin was not measured in the trials studied here,
and we advocate that future trials in enteric fever must incorpo-
rate pharmacokinetic measurements to allow correct analysis of
PK-PD parameters.
In summary, our data support the proposition that an azithro-
mycin MIC of 16 g/ml defines a wild-type population of S.
Typhi isolates (24, 25). We further show that this MIC defines a
population of isolates associated with a satisfactory response to
azithromycin treatment in uncomplicated disease and propose
tentative disk susceptibility breakpoints that will detect such iso-
lates. We recognize that there is insufficient clinical and PK-PD
data to determine the response to treatment in infections with S.
Typhi isolates with an azithromycin MIC of16 g/ml or gener-
ally with S. Paratyphi A infections. We are aware of sporadic cases
of treatment failure with S. Paratyphi A infections with azithro-
mycin MIC of16 g/ml (22, 32) and increasing reports of iso-
lates from enteric fever patients with an azithromycinMIC of16
g/ml (33, 34). We suspect that the use of azithromycin to treat
enteric fever may be driving their emergence. Clearly, further
studies in this area are essential, as the therapeutic options for
enteric fever continue to narrow. Currently, third-generation
cephalosporins or fluoroquinolones are the only real options
available for enteric fever infections that areMDRandnonsuscep-
tible to ciprofloxacin, yet increasing reports of resistance with
these agentsmean that azithromycinmay itself emerge as a crucial
drug in the future treatment and control of enteric fever.
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